The Questionable Practice That Permeates Oncology Clinical Trials
Most oncology phase 1 trials use a simplistic, outdated dose-finding technique, and experts agree that change is needed.
Endocrine Cancer
ENDOCRINE CANCER ADVISOR
FEATURED CONTENT
-
-
Integrative Oncology: Using Evidence-Informed Medicine to Improve Patient Outcomes and Quality of Life
Lifestyle-based integrative treatment approaches — deemed scientifically sound by the field’s proponents — merge conventional and complementary treatments. -
The FDA Approval Process Needs Refinement, Not a Total Overhaul
Even though overall drug development times have not changed, questions about the clinical benefit of the drugs that have been approved through expedited pathways are being raised. -
How Durable Are Responses to Targeted Therapies Across Single-Arm Cancer Trials?
Drugs approved based on changes to surrogate biomarker levels may be subject to measurement bias, according to investigators. -
Reporting Mechanisms for Conflict of Interest Disclosures in Medicine Need Standardization
ASCO officials examined the discrepancies in financial disclosures across platforms and call for a simplified system.
ENDOCRINE CANCER NEWS
Therapeutic Advancements Have Facilitated Surgery Optimization, ASCO Officials Report
No Link Found Between Hepatitis C Infection and Extrahepatic Cancers
Pediatric Thyroid Cancer Rates Are Rising, but Some Experts Doubt the Significance
Factors Associated With Thyroid Cancer Overtreatment Identified
Radiation From CT Scans Linked to Thyroid Cancer, Leukemia
Want to read more?
Please login or register first to view this content.
Next post in Endocrine Cancer
